BREAKING
Protagonist Therapeutics Jumps 7.0% in Broad Rally 9 hours ago Valaris Limited Drops 6.7% in Broad Selloff 10 hours ago Talos Energy Inc. Drops 6.2% Amid Sector-Wide Selling 10 hours ago Northern Oil and Gas, Inc. Drops 5.2% in Broad Selloff 10 hours ago Bank7 Corp. Tops Q1 Forecasts With $1.25 EPS, 20.2% Above Consensus 11 hours ago JetBlue Airways Corporation Surges 15.1% in Broad Rally 11 hours ago Celanese Corporation Shares Dropping 5.5% 11 hours ago Akamai Technologies, Inc. Shares Dropping 5.3% 11 hours ago Amazon.com, Inc. (AMZN) Jumps 5.2% to $232.68 11 hours ago Boot Barn Holdings, Inc. Shares Jumping 5.2% 11 hours ago Protagonist Therapeutics Jumps 7.0% in Broad Rally 9 hours ago Valaris Limited Drops 6.7% in Broad Selloff 10 hours ago Talos Energy Inc. Drops 6.2% Amid Sector-Wide Selling 10 hours ago Northern Oil and Gas, Inc. Drops 5.2% in Broad Selloff 10 hours ago Bank7 Corp. Tops Q1 Forecasts With $1.25 EPS, 20.2% Above Consensus 11 hours ago JetBlue Airways Corporation Surges 15.1% in Broad Rally 11 hours ago Celanese Corporation Shares Dropping 5.5% 11 hours ago Akamai Technologies, Inc. Shares Dropping 5.3% 11 hours ago Amazon.com, Inc. (AMZN) Jumps 5.2% to $232.68 11 hours ago Boot Barn Holdings, Inc. Shares Jumping 5.2% 11 hours ago
ADVERTISEMENT
AlphaGraphs

ABBV Infographic: AbbVie’s Q1 2023 earnings and revenue decline

Pharmaceutical company AbbVie, Inc. (NYSE: ABBV) reported a decrease in first-quarter 2023 adjusted earnings and revenues. The company also provided guidance for fiscal 2023. Total revenues decreased 9.7% year-over-year to $12.23 billion, reflecting weakness in the main operating segments. At $2.46 per share, adjusted net income was lower than the $3.16 per share reported in […]

April 27, 2023 1 min read

Pharmaceutical company AbbVie, Inc. (NYSE: ABBV) reported a decrease in first-quarter 2023 adjusted earnings and revenues. The company also provided guidance for fiscal 2023. Total revenues decreased 9.7% year-over-year to $12.23 billion, reflecting weakness in the main operating segments. At $2.46 per share, adjusted net income was lower than the $3.16 per share reported in […]

Pharmaceutical company AbbVie, Inc. (NYSE: ABBV) reported a decrease in first-quarter 2023 adjusted earnings and revenues. The company also provided guidance for fiscal 2023.

AbbVie Q1 2023 earnings infographic

Total revenues decreased 9.7% year-over-year to $12.23 billion, reflecting weakness in the main operating segments.

At $2.46 per share, adjusted net income was lower than the $3.16 per share reported in the prior-year period. First-quarter unadjusted profit dropped to $239 million or $0.13 per share from $4.49 billion or $2.51 per share in the first quarter of 2022.

“This year is off to an excellent start, with first-quarter revenues and EPS ahead of our expectations, driven by strong commercial execution across all areas of our diversified portfolio,” said Richard A. Gonzalez, CEO of AbbVie.

Prior Performance

  • AbbVie-Q4-2022-Earnings-Infographic
  • AbbVie Q3 2022 earnings infographic
  • Abbvie Q2 2022 earnings infographics

ADVERTISEMENT